Original Articles
CJ Mbah, NL Umegbo and NJ Nwod
Abstract
Nimodipine can be used to treat conditions such as aneurysms, subarachnoid hemorrhage, acute myocardial infarction, arrhythmia, hypertension, congestive heart failure, hypertrophic cardiomyopathy, vasospastic angina and Prenzmetal's angina. The purpose of this study was to investigate the effects of cosolvents and surfactants on the pharmacokinetics of nimodipine in rats. A single dose of nimodipine was administered orally (15 mg/kg) to rats in 20 % w/v cosolvent and 1 % w/v surfactant solution respectively. Compared with the control group, the area under the plasma concentration-time curve (AUC0-∞) of nimodipine and the peak plasma concentration (Cmax) were increased significantly (p